NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced on Wednesday, February 15, 2023, its fourth-quarter and full-year 2022 earnings forecast prior to the opening of U.S. financial markets. announced that it will report financial results for The company will hold a conference call and simultaneous webcast later that day at 8:00 am Eastern Time.
Conference call information
Please visit the Investors page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events for information on the conference call and to view the live webcast. Conference call and webcast replays will be archived on the company’s website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, providing access from academic institutions, research hospitals and non-profits to small and medium enterprises. We work with innovators from biotech companies to major global pharmaceutical companies. Royalty Pharma has built a royalty portfolio that entitles it to receive payments based directly on top-line sales of many industry-leading therapies. Royalty Pharma directly and indirectly funds innovation in the biopharmaceutical industry. Direct, when partnering with a company to co-fund late-stage clinical trials or new product launches in exchange for future royalties, and indirect, when obtaining existing royalties from the original innovator. Royaly Pharma’s current portfolio includes Vertex’s Trikafta, Kalydeco, Orkambi, Symdeko, Biogen’s Tysabri, AbbVie, Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Over 35 commercial product royalties are included, including Johnson. & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy and 12 development stage product candidates. For more information, please visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772